Quality measurement in adult cardiac surgery, part 2: statistical considerations in composite measure scoring and provider rating. Ann Thorac Surg. 2007;83(suppl):S13 S26. doi: 10.1016/j. athoracsur.2007.01.055. 204. Brinkman WT, Herbert MA, Prince SL, Magee MJ, Dewey TM, Smith RL, Edgerton JR, Head SJ, Ryan WH, Mack MJ. Preoperative beta- blocker usage: is it really worthy of being a quality indicator? Ann Thorac Surg. 2011;92:788 795. doi: 10.1016/j.athoracsur.2011.03.088. 205. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protec- tion using beta-blockers: a critical review of the evidence. J Am Coll Cardiol. 2007;50:563 572. doi: 10.1016/j.jacc.2007.04.060. 206. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortal- ity among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489 497. doi: 10.1056/NEJM199808203390801. 207. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta block- ade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730 1737. 208. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9 13. J, Wikstrand J, El Allaf D, V tovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, J nosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospital- izations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF): MERIT-HF Study Group. JAMA. 2000;283:1295 1302. 210. Packer M, CoatsAJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651 1658. doi: 10.1056/NEJM200105313442201. 211. Dargie HJ. 